Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
27.67
Dollar change
-1.31
Percentage change
-4.52
%
IndexRUT P/E- EPS (ttm)-2.41 Insider Own21.93% Shs Outstand188.99M Perf Week3.79%
Market Cap5.23B Forward P/E- EPS next Y-3.57 Insider Trans-12.39% Shs Float147.54M Perf Month12.39%
Income-438.86M PEG- EPS next Q-1.13 Inst Own76.12% Short Float11.52% Perf Quarter5.69%
Sales217.76M P/S24.01 EPS this Y34.89% Inst Trans-2.06% Short Ratio8.09 Perf Half Y-4.59%
Book/sh-6.51 P/B- EPS next Y-38.83% ROA-66.49% Short Interest17.00M Perf Year-17.35%
Cash/sh2.15 P/C12.89 EPS next 5Y26.80% ROE- 52W Range21.62 - 44.32 Perf YTD-31.46%
Dividend Est.- P/FCF- EPS past 5Y-13.29% ROI-88.62% 52W High-37.57% Beta1.06
Dividend TTM- Quick Ratio3.19 Sales past 5Y117.77% Gross Margin96.56% 52W Low27.98% ATR (14)1.54
Dividend Ex-Date- Current Ratio3.19 EPS Y/Y TTM38.26% Oper. Margin-244.62% RSI (14)55.91 Volatility5.65% 6.00%
Employees550 Debt/Eq- Sales Y/Y TTM2209.77% Profit Margin-201.53% Recom1.33 Target Price49.53
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q20.69% Payout- Rel Volume0.87 Prev Close28.98
Sales Surprise63.07% EPS Surprise14.28% Sales Q/Q-33.22% EarningsNov 12 BMO Avg Volume2.10M Price27.67
SMA206.11% SMA508.51% SMA2003.39% Trades Volume1,827,599 Change-4.52%
Date Action Analyst Rating Change Price Target Change
Oct-16-24Initiated Scotiabank Sector Outperform
Oct-03-24Initiated Oppenheimer Perform
Sep-04-24Initiated Piper Sandler Overweight $46
Mar-21-24Resumed Raymond James Outperform $45
Jan-31-24Initiated BMO Capital Markets Market Perform $37
Dec-08-23Initiated Wells Fargo Overweight $58
Dec-08-23Initiated Wells Fargo Overweight
Nov-07-23Initiated Citigroup Buy $42
Oct-24-23Initiated Cantor Fitzgerald Overweight $50
Jul-18-23Downgrade Jefferies Buy → Hold $24 → $33
Dec-03-24 08:00AM
Nov-26-24 09:10AM
06:50AM
Nov-25-24 04:16PM
09:40AM
09:03AM Loading…
09:03AM
04:38AM
Nov-22-24 07:11PM
02:16PM
Nov-21-24 05:43PM
Nov-19-24 02:44PM
Nov-18-24 11:15AM
05:30AM
Nov-12-24 08:39PM
08:45AM
07:40AM Loading…
07:40AM
07:30AM
Nov-05-24 07:30AM
Oct-31-24 10:01AM
Oct-24-24 07:30AM
Oct-04-24 05:17AM
Oct-03-24 07:30AM
Oct-01-24 05:00AM
Sep-30-24 01:17PM
12:09PM
07:30AM
Sep-27-24 06:00PM
Sep-17-24 07:30AM
Sep-12-24 01:01PM
Sep-11-24 01:44PM
07:35AM Loading…
07:35AM
Sep-10-24 04:45PM
04:45PM
Sep-06-24 07:30AM
Aug-30-24 04:03PM
01:10PM
10:50AM
Aug-29-24 07:30AM
Aug-28-24 07:30AM
Aug-26-24 07:30AM
Aug-21-24 07:43AM
Aug-19-24 07:30AM
Aug-08-24 07:30AM
Aug-01-24 08:40AM
07:41AM
07:30AM
Jul-23-24 07:30AM
Jul-05-24 04:31PM
Jun-27-24 02:21PM
Jun-26-24 10:12PM
Jun-18-24 07:30AM
Jun-10-24 07:30AM
Jun-06-24 07:30AM
Jun-05-24 01:35PM
Jun-04-24 04:19PM
10:15AM
08:00AM
07:30AM
Jun-03-24 04:01PM
May-29-24 04:01PM
May-27-24 12:32PM
May-24-24 07:30AM
May-15-24 07:30AM
May-14-24 07:30AM
May-13-24 07:30AM
May-03-24 06:22AM
May-02-24 10:55PM
10:27AM
07:40AM
07:30AM
07:00AM
03:00AM
May-01-24 08:10AM
Apr-25-24 10:02AM
Apr-10-24 07:30AM
Apr-07-24 01:15PM
Mar-27-24 09:25AM
Mar-20-24 07:30AM
Mar-05-24 11:53PM
Mar-04-24 04:17PM
04:05PM
03:00AM
02:30AM
02:30AM
02:30AM
Feb-22-24 08:40AM
07:53AM
07:52AM
07:30AM
Feb-15-24 10:00AM
06:54AM
Feb-07-24 07:34AM
07:22AM
Feb-06-24 07:30AM
Feb-05-24 07:30AM
Feb-02-24 07:00AM
Jan-30-24 07:00AM
Jan-29-24 12:35PM
Jan-18-24 07:59PM
07:00AM
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kumar NeilChief Executive OfficerNov 19 '24Sale22.4127,389613,8264,897,443Nov 20 08:00 PM
STEPHENSON BRIAN CSecretary, Treasurer & CFONov 19 '24Sale22.414,15693,13793,758Nov 20 07:57 PM
BRIAN STEPHENSONOfficerNov 19 '24Proposed Sale22.354,15692,887Nov 19 04:28 PM
NEIL KUMARDirectorNov 19 '24Proposed Sale22.3527,389612,144Nov 19 04:24 PM
KKR Genetic Disorder L.P.10% OwnerSep 13 '24Sale25.755,800,000149,350,00025,260,971Sep 17 06:44 PM
KKR Genetic Disorder L.P.AffiliateSep 13 '24Proposed Sale26.955,800,000156,310,000Sep 13 05:04 PM
Kumar NeilChief Executive OfficerAug 19 '24Sale24.6927,389676,2564,897,443Aug 20 06:31 PM
STEPHENSON BRIAN CSecretary, Treasurer & CFOAug 19 '24Sale24.694,155102,59085,192Aug 20 06:27 PM
BRIAN STEPHENSONOfficerAug 19 '24Proposed Sale24.404,155101,382Aug 19 04:29 PM
NEIL KUMARDirectorAug 19 '24Proposed Sale24.4027,389668,292Aug 19 04:27 PM
Scott Randal W.DirectorJun 04 '24Sale31.301,50046,9504,000Jun 05 04:53 PM
Scott Randal W.DirectorJun 03 '24Sale28.841,00028,8435,500Jun 05 04:53 PM
Scott Randal W.DirectorMar 01 '24Sale34.002,50085,0006,500Mar 05 04:00 PM
Valantine HannahDirectorFeb 15 '24Option Exercise8.452,91524,6324,679Feb 20 04:03 PM
Valantine HannahDirectorFeb 15 '24Sale37.752,915110,0411,764Feb 20 04:03 PM
Valantine HannahDirectorJan 16 '24Option Exercise8.452,91524,6324,679Jan 18 04:10 PM
Valantine HannahDirectorJan 16 '24Sale37.972,915110,6831,764Jan 18 04:10 PM
MCCORMICK FRANKDirectorDec 26 '23Sale42.06100,0004,206,000627,689Dec 28 04:00 PM
Scott Randal W.DirectorDec 18 '23Sale40.002,00080,0009,000Dec 20 04:00 PM
Valantine HannahDirectorDec 15 '23Option Exercise8.452,91524,6324,679Dec 19 04:00 PM
Valantine HannahDirectorDec 15 '23Sale36.122,915105,2901,764Dec 19 04:00 PM